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INTRODUCTION
Lung cancer is the leading cause of cancer deaths
worldwide (1). Non-small-cell lung carcinoma (NSCLC),
which represents approximately 80% of all lung cancer
cases, is frequently diagnosed at advanced stages of the
disease and is associated with short survival time. Although
the prognosis of this disease remains poor, significant
advances in the genetics and treatment of NSCLC have
been made in recent years.
In 2007, Soda et al. (2) identified the transforming EML4-
ALK fusion gene in 6.7% of NSCLC patients. This fusion
transcript, which presents potent oncogenic activity both in
vitro and in vivo (2,3), is formed by the translocation of the
echinoderm microtubule-associated protein-like 4 (EML4)
gene (2p21) and anaplastic lymphoma kinase (ALK) gene
(2p23). Subsequent studies have shown that between two
and eight percent of all NSCLC cases may harbor ALK
rearrangements, which are almost always mutually exclu-
sive with EGFR and KRAS mutations. Moreover, these
patients are frequently younger, non- or light smokers
and have adenocarcinomas (2,4-23). Recently, crizotinib,
an orally available small-molecule inhibitor of the ALK
tyrosine kinase, was approved for the treatment of ALK-
rearranged NSCLC patients, with successful results (24-29).
The two most widely used methods for the diagnosis of
ALK-rearranged NSCLC are fluorescence in situ hybridiza-
tion (FISH) and immunohistochemistry.
Because there is no information about the prevalence and
clinical characteristics of ALK-rearranged NSCLC in Latin
America in the literature, the aim of this study was to
evaluate NSCLC with ALK rearrangement in Brazilian
patients.
MATERIALS AND METHODS
Case Selection
This study included 62 consecutive NSCLC cases received
from August 2010 to September 2011 for ALK rearrangement
testing using FISH (30) by Consultoria em Patologia, a large
Anatomic Pathology and Molecular Pathology reference
laboratory located in Botucatu, Sa˜o Paulo State, Brazil.
Tissues from small biopsies and lung resection specimens
were used. The ages and genders of the patients were
registered.
Fluorescence in situ hybridization (FISH)
FISHwas performed on formalin-fixed, paraffin-embedded
tumor samples using a probe specific to the ALK locus (Vysis
LSI ALK dual color, break apart rearrangement probe; Abbott
Molecular, Des Plaines, IL, USA) according to the manufac-
turer’s instructions. The FISH results were analyzed under a
fluorescence microscope (Zeiss Axio Imager M1, Carl Zeiss
AG, Oberkochen, Germany) with the appropriate filters
(Chroma Technology GmbH, Fuerstenfeldbruck, Germany)
and Metafer 4 software (MetaSystems, Altlussheim, Ger-
many). FISH-positive cases were defined as those in which
more than 15% of the cells (at least 40 neoplastic cells were
counted) presented with split orange and green signals or an
isolated orange signal, as previously described (31,32).
Immunohistochemistry
For comparison with FISH results, ALK protein expres-
sion was determined by immunohistochemistry using the
mouse monoclonal antibody 5A4 (code ab17127, ABCAM,
Cambridge, MA, USA), which was found to show high
concordance with ALK gene status, as determined by
molecular tests (13,14,23,33-36). Briefly, 3-mm-thick unstained
histologic sections of lung carcinoma tissue were used in
all cases. The sections were deparaffinized in xylene and
rehydrated in a graded series of alcohol in phosphate-
buffered saline. The sections then were submitted to antigen
retrieval in a microwave. Subsequently, slides were incu-
bated overnight with the 5A4 antibody at a pre-standardized
concentration (1:200), washed with phosphate-buffered
saline, and incubated with Novocastra Novolink Polymer
Detection System (Leica Biosystems Newcastle Ltd.,
Newcastle upon Tyne, UK). Diaminobenzidine was used as
the chromogen, and sections were counterstained with
hematoxylin and coverslipped. A case was considered
positive for ALK if $10% of the tumor cells showed intense
cytoplasmic immunostaining.
RESULTS
Of the 62 NSCLC cases included in this study, two (3.2%)
showed ALK rearrangement by FISH: one case presented an
isolated orange signal along with one fusion signal in tumor
cells, and the other showed split orange and green signals
along with one fusion signal. These two FISH-positive cases
were also positive for ALK by immunohistochemistry, with
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strong cytoplasmic immunostaining in virtually all tumor
cells. All of the other sixty FISH-negative cases were also
negative for ALK using immunohistochemistry.
Both of the patients with FISH- and ALK immunohisto-
chemistry-positive NSCLC were men (36 years old and 45
years old; mean: 40 years). One of them had no history of
tobacco smoking, and the other was a light smoker who had
stopped smoking some months prior to the diagnosis. The
group of patients (n = 60) presenting ALK-negative tumors
by FISH varied in age from 32 to 87 years (mean: 58 years;
median: 59 years), and most of these patients were male (33
patients).
According to the new international multidisciplinary
classification of lung adenocarcinomas proposed by the
International Association for the Study of Lung Cancer, the
American Thoracic Society and the European Respiratory
Society (37), tumors from the two patients with ALK-positive
FISH were classified as invasive adenocarcinoma, acinar
predominant. One tumor had papillary areas, and the other
was rich in mucinous areas. The 36-year-old patient with
invasive adenocarcinoma, acinar predominant with papillary
areas, was also tested for EGFR and KRAS mutations; the
tumor was negative for both mutations. Figure 1 presents the
morphologic characteristics of the two ALK-positive cases,
including FISH and immunohistochemical findings.
DISCUSSION
Clinical characteristics associated with ALK rearrange-
ment in NSCLC include adenocarcinoma histology, younger
age at diagnosis, and non- or light smoker status, similar to
those described for EGFR mutations. The prevalence of
NSCLCs with ALK fusion varies from 2% to 8% in the
literature, and most studies have been conducted in Asian
countries or in the United States of America. Table 1
presents the frequency of ALK-rearranged NSCLC in several
countries. In Japan, the prevalence of lung cancer with ALK
rearrangement varied widely, from 2.4% to 6.7% (2,16,19). In
Korea, the frequency of ALK-positive NSCLC ranged from
3.7% to 4.2% (11,13,14). In China, it was approximately 5%
(4,12,15). In the USA, the prevalence varied from 5.6 to 8.2%
(17,23). These findings show that ethnicity likely does not
strongly influence the prevalence of ALK-rearranged lung
carcinomas, which is in contrast to EGFR- and KRAS-
mutated tumors (38-41).
To the best of our knowledge, however, no information
about the prevalence and clinical characteristics of these
tumors in Latin America, including Brazil, is available in the
literature.
In the present study, 3.2% (2 out of 62) of NSCLC cases in
Brazilian patients were ALK fusion positive by FISH. These
two male patients were younger than those with ALK-
negative FISH, had a history of no or light smoking, and
their tumors presented invasive adenocarcinoma histology
similar to that described in the literature. Both tumors were
histologically classified as acinar predominant: one tumor
had papillary areas, and the other was rich in mucinous
areas.
Consistent with the results of other studies (13,14,23,33-
35), a high concordance between FISH and immunohisto-
chemistry results for the detection of ALK-positive NSCLCs
was found in the present study. Although FISH remains the
gold standard technique for the diagnosis of ALK-rear-
ranged lung carcinoma, immunohistochemistry may play
an important role in the determination of ALK status in
NSCLC in the near future. Because data regarding the role
of immunohistochemistry in the detection of ALK-positive
lung cancer are limited in the literature, additional studies
are necessary.
The use of crizotinib has changed the history of NSCLC
treatment, with dramatic results in patients with ALK-
rearranged tumors. A recent phase I/II clinical trial showed
that 47 of 82 (57%) patients with ALK fusion-positive lung
tumors confirmed by FISH had objective responses to
crizotinib, and an additional 27 (33%) patients displayed
stable disease (9). These data highlight that the diagnosis of
ALK-rearranged NSCLC is crucial.
As previously stated, the present study is the first in Latin
America to present clinicopathologic information regarding
ALK-rearranged NSCLC in patients from this geographic
area. Further studies are encouraged to expand our knowl-
edge on ALK-positive NSCLC in Latin America and Brazil.
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Figure 1 - ALK-rearranged NSCLCs. A. Invasive adenocarcinoma,
acinar predominant with papillary areas, in a 36-year-old male
patient (case 1). B. FISH of case 1 showing one isolated orange
signal along with one fusion signal (positive for ALK rearrange-
ment). C. ALK expression in case 1: diffuse and intense
cytoplasmic immunostaining. D. Invasive adenocarcinoma, acinar
predominant with mucinous areas, in a 45-year-old male patient
(case 2). E. FISH of case 2 showing split orange and green signals
along with one fusion signal (positive for ALK rearrangement). F.
ALK expression in case 2: intense cytoplasmic immunostaining in
virtually all tumor cells.
Table 1 - Prevalence of ALK-rearranged NSCLC in
different countries.
Authors, year of
publication Country ALK-rearranged tumors
Soda et al., 2007 (2) Japan 6.7% (n=75)
Rodig et al., 2009 (17) USA 5.6% (n=358)
Wong et al., 2009 (4) China 4.9% (n=266)
Sakairi et al., 2010 (19) Japan 6.4% (n=109)
Takahashi et al., 2010 (16) Japan 2.4% (n=211)
Sun et al., 2010 (15) China 5.7% (n=52)
Paik et al., 2011 (11) Korea 3.8% (n=735)
Li et al., 2011 (12) China 5% (n=202)
Kim et al., 2011 (13) Korea 3.7% (n=449)
Paik et al., 2011 (14) Korea 4.2% (n=453)
Yang et al., 2012 (23) USA 8.2% (n=300)
Lopes et al. (present study) Brazil 3.2% (n=62)
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